Search for a trial

PRISMA: Pediatric oncologic Research on Improving Speed, Memory and Attention
THE EFFICACY OF NEUROFEEDBACK TO IMPROVE ATTENTION AND MEMORY IN CHILDHOOD BRAIN TUMOUR SURVIVORS: A DOUBLE BLIND, RANDOMIZED, PLACEBO CONTROLLED TRIAL

The aim of this study is to investigate the efficacy of neurofeedback to improve attention and memory in children that have been treated for a brain tumour. If the neurofeedback proves to be effective, we will strive to implement this training for…

The effect of modafinil on fatigue, cognition and functional connectivity in low-grade glioma patients: a double-blind randomized trial.

(1) investigating the influence of modafinil on fatigue, cognitive functioning, and quality of life of LGG patients, (2) assessing the correlation between (changes in) fatigue, cognition, and quality of life on the one hand, and functional…

Glioma: Reducing Anxiety by conSuming cannabinoidS - GRASS study. Treating anxiety with CBD in glioma patients - A randomized-controlled trial

To investigate the effect of a three-week treatment with cannabidiol (CBD) on anxiety in patients with a primary brain tumor that have no active oncological treatment. Depression, fatigue and general quality of life are secondary outcome measures.…

A phase 3, multicenter, randomized, double-blind, placebo-controlled study of AG-881 in subjects with residual or recurrent grade 2 glioma with and IDH1 or IDH2 mutation

This study has been transitioned to CTIS with ID 2024-512961-15-00 check the CTIS register for the current data. Primary:• The primary objective of the study is to demonstrate the efficacy of vorasidenib based on radiographic progression-free…

A Randomized, Placebo Controlled Phase 3 Study of ABT-414 with Concurrent Chemoradiation and Adjuvant Temozolomide in Subjects with Newly Diagnosed Glioblastoma (GBM) with Epidermal Growth Factor Receptor (EGFR) Amplification (Intellance 1)

To determine whether the addition of ABT-414 to concomitant radiotherapy and temozolomide prolongs overall survival (OS) in subjects with newly diagnosed GBM harboring EGFR amplification.